HSP90 inhibitor 17-AAG suppresses the proliferation of FLT3-ITD/D835 mutant AML cells

被引：0
|
作者：
Katayama, Kazuhiro [1 ]
Noguchi, Kohji [1 ]
Sugimoto, Yoshikazu [1 ]
机构：
[1] Keio Univ, Fac Pharm, Div Chemother, Tokyo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-1015
引用
收藏
页码：294 / 294
页数：1
相关论文
共 50 条
  • [31] The HSP 90 inhibitor, 17-AAG, increases gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia (AML) cells
    Walter, Roland B.
    Bernstein, Irwin D.
    BLOOD, 2007, 110 (11) : 480A - 480A
  • [32] Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
    Weber, Helga
    Valbuena, Jose R.
    Barbhuiya, Mustafa A.
    Stein, Stefan
    Kunkel, Hana
    Garcia, Patricia
    Bizama, Carolina
    Riquelme, Ismael
    Espinoza, Jaime A.
    Kurtz, Stephen E.
    Tyner, Jeffrey W.
    Francisco Calderon, Juan
    Corvalan, Alejandro H.
    Grez, Manuel
    Pandey, Akhilesh
    Leal-Rojas, Pamela
    Roa, Juan C.
    ONCOTARGET, 2017, 8 (16) : 26169 - 26184
  • [33] The HSP90 Inhibitor, 17-AAG, Influences the Activation and Proliferation of T Lymphocytes via AKT/GSK3β Signaling in MRL/lpr Mice
    Hong, Liang-Jian
    Chen, Ai-Jun
    Li, Feng-Zeng
    Chen, Ke-Jun
    Fang, Sheng
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 4605 - 4612
  • [34] Synergistic toxicity of tyrosine kinase inhibitors with Hsp90 inhibitor 17-AAG in lung cancer cell line
    Damaraju, V. L.
    Wilson, M.
    Kuzma, M.
    Mowles, D.
    Cass, C. E.
    Sawyer, M. B.
    EJC SUPPLEMENTS, 2010, 8 (07): : 59 - 60
  • [35] Evolution of FLT3-ITD and D835 activating point mutations in relapsing acute myeloid leukemia and response to salvage therapy
    Tiesmeier, J
    Müller-Tidow, C
    Westermann, A
    Czwalinna, A
    Hoffmann, M
    Krauter, J
    Heil, G
    Ganser, A
    Serve, H
    Verbeek, W
    LEUKEMIA RESEARCH, 2004, 28 (10) : 1069 - 1074
  • [36] Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation
    Heng, Hao
    Zhi, Yanle
    Yuan, Haoliang
    Wang, Zhijie
    Li, Hongmei
    Wang, Shuxian
    Tian, Jieyi
    Liu, Haichun
    Chen, Yadong
    Lu, Tao
    Ran, Ting
    Lu, Shuai
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 163 : 195 - 206
  • [37] Acquired resistance to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines
    Gaspar, Nathalie
    Sharp, Swee
    Pacey, Simon
    Jones, Chris
    Walton, Mike
    Vassal, Gilles
    Pearson, Andrew
    Workman, Paul
    NEURO-ONCOLOGY, 2008, 10 (03) : 374 - 374
  • [38] Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3-ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations
    Yamatani, Kotoko
    Ai, Tomohiko
    Saito, Kaori
    Yang, Haeun
    Suzuki, Koya
    Hori, Atsushi
    Murakami-Tonami, Yuko
    Zhang, Weiguo
    Carter, Bing Z.
    Kinjo, Sonoko
    Ikeo, Kazuho
    Kazuhiro, Katayama
    Harada, Hironori
    Miida, Takashi
    Shah, Neil P.
    Konopleva, Marina Y.
    Hayashizaki, Yoshihide
    Andreeff, Michael
    Tabe, Yoko
    BLOOD, 2019, 134
  • [39] 17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1α and ILK in mouse RPE cells
    Ye Qing Wang
    Xiao Mei Zhang
    Xiao Dan Wang
    Bin Jie Wang
    Wei Wang
    Molecular Biology Reports, 2010, 37 : 1203 - 1209
  • [40] 17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1α and ILK in mouse RPE cells
    Wang, Ye Qing
    Zhang, Xiao Mei
    Wang, Xiao Dan
    Wang, Bin Jie
    Wang, Wei
    MOLECULAR BIOLOGY REPORTS, 2010, 37 (03) : 1203 - 1209
12345